ArticleMayo Clinic proceedings. Digital health2026
Real-World Validation of PinPoint Blood Tests in the NHS: Multivariable Machine Learning to Predict Cancer Risk in Primary Care Urgent Referrals.
Article in Mayo Clinic proceedings. Digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To validate the United Kingdom Conformity Assessed-marked PinPoint blood tests, which use machine learning models and routinely available blood analytes to estimate cancer risk in adults referred on urgent suspected cancer pathways in National Health Service (NHS) England. Patients and Methods: This work comprises a large-scale, prospective, observational, real-world NHS service evaluation of 9 blood tests, carried out from December 21, 2020 to July 31, 2025. Total of 16,481 patients with urgent suspected cancer referrals were enrolled across 5 secondary care Trusts and 170 General Practitioner surgeries. Real-world performance of the tests was evaluated using a range of diagnostic accuracy statistics. Results: Five tests have performance indicating potential clinical utility. Receiver operating characteristic area-under-curve scores (95% CI) for these were: Upper gastrointestinal=0.86 (0.81-0.90), Gynecological=0.81 (0.77-0.85), Lung=0.79 (0.74-0.84), Head & Neck=0.73 (0.68-0.78), and Lower gastrointestinal=0.72 (0.67-0.78), Prioritization of the 10% of highest-risk patients would reduce the number needed to investigate to detect one cancer by a factor of 2.6-6.1. Conclusion: This work shows the potential of these tests to improve urgent suspected cancer referral pathways. High-risk patients could be diagnosed more rapidly, leading to potential earlier-stage diagnosis and a better diagnostic experience. Low-risk patients could avoid unnecessary invasive medical testing for cancer. The software can be deployed rapidly across the NHS, without the need for additional hardware.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.